Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?

Liver International

Volumn 38, Issue , 2018, Pages 7-13

  Asselah, Tarik ^a   Marcellin, Patrick ^a   Schinazi, Raymond F ^b  

^a INSERM   (France)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chronic hepatitis C; compliance; genotype; HCV elimination; people who inject drugs; screening

Indexed keywords

ANTIVIRUS AGENT; ELBASVIR PLUS GRAZOPREVIR; GLECAPREVIR PLUS PIBRENTASVIR; SOFOSBUVIR PLUS VELPATASVIR; SOFOSBUVIR PLUS VELPATASVIR PLUS VOXILAPREVIR;

COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; HEALTHY LIFESTYLE; HEPATITIS C; HUMAN; PATIENT REFERRAL; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; CHRONIC HEPATITIS C; DRUG EFFECT; HEPACIVIRUS; MEDICATION COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUSTAINED VIROLOGIC RESPONSE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUSTAINED VIROLOGIC RESPONSE;

EID: 85041834913     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13673     Document Type: Review

References (27)

1. Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47-57.
2. Schinazi RF, Asselah T. From HCV to HBV cure. Liver Int. 2017;37(Suppl 1):73-80.
3. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks post treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51:1122-1126.
4. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135:821-829.
5. Afdhal N, Everson GT, Calleja JL, et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017;24:823-831.
6. Kim RW, Mannalithara A, Lee H, Osinusi A, Schall REA, Brainard DM. Survival benefit of direct acting antiviral therapy in patients with decompensated cirrhosis. Hepatology. 2017;66:LB27.
7. Younossi ZM, Stepanova M, Jacobson IM, et al. Changes in patient-reported outcomes in direct acting antiviral-naïve chronic hepatitis C patients with or without cirrhosis: the impact of sofosbuvir and velpatasvir with or without voxilaprevir. Aliment Pharmacol Ther. 2018;47:259-267.
8. Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother. 2014;15:121-130.
9. Cheng G, Yu M, Peng B, et al. GS-5816, a second-generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier. J Hepatol. 2013;58(Suppl 1):S484.
10. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599-2607.
11. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608-2617.
12. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618-2628.
13. Asselah T, Bourgeois S, Pianko S, et al. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int. 2018; in press. https://doi.org/10.1111/liv.13534.
14. Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in patients with chronic HCV infection: 2 Phase 3 Randomized Trials. Gastroenterology. 2017;153:113-122.
15. Ng TI, Tripathi R, Reisch T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir. Antimicrob Agents Chemother. 2017;62:pii: AAC.01620-17.
16. Maviret Summary of Product Characteristics; Accessed August 2017.
17. Zeuzem S, Foster GR, Wang S, et al. 8- or 12-week Glecaprevir/Pibrentasvir in Non-cirrhotic HCV Genotype 1 or 3. NEJM. 2018; in press.
18. Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018. In press.
19. Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377:1448-1455.
20. Asante-Appiah E, Curry S, McMonagle P, et al. Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor Elbasvir in hepatitis C virus GT4 Replicons. Antimicrob Agents Chemother. 2017;61:pii: e00363-17.
21. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1-13.
22. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537-1545.
23. Dore GJ, Altice F, Litwin AH, et al. Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165:625-634.
24. Asselah T, Reesink H, Gerstoft J, et al. High efficacy of Elbasvir and grazoprevir with or without Ribavirin in 103 treatment-naive and experienced patients with HCV genotype 4 infection: A pooled analysis. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases, November 1317, San Francisco, USA; abstract 251.
25. Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134-2146.
26. Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389-397.
27. Lau G. Shortening HCV therapy: science meets public health. Lancet Gastroenterol Hepatol. 2017;2:771-772.